000305584 001__ 305584
000305584 005__ 20251102023529.0
000305584 0247_ $$2doi$$a10.1016/S1470-2045(25)00426-7
000305584 0247_ $$2pmid$$apmid:41167226
000305584 0247_ $$2ISSN$$a1470-2045
000305584 0247_ $$2ISSN$$a1474-5488
000305584 0247_ $$2altmetric$$aaltmetric:182962476
000305584 037__ $$aDKFZ-2025-02243
000305584 041__ $$aEnglish
000305584 082__ $$a610
000305584 1001_ $$aSanz, Jaime$$b0
000305584 245__ $$aMeasurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee.
000305584 260__ $$aLondon$$bThe Lancet Publ. Group$$c2025
000305584 3367_ $$2DRIVER$$aarticle
000305584 3367_ $$2DataCite$$aOutput Types/Journal article
000305584 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761918006_171915$$xReview Article
000305584 3367_ $$2BibTeX$$aARTICLE
000305584 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305584 3367_ $$00$$2EndNote$$aJournal Article
000305584 520__ $$aMeasurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance from the European Society for Blood and Marrow Transplantation, provides practical recommendations for incorporating MRD assessment into clinical decision making during the transplantation process, the application of which remains challenging in acute myeloid leukaemia due to technical limitations and the limited availability of standardised, evidence-based approaches. Available methods include reverse transcription quantitative PCR, digital droplet PCR, next-generation sequencing, and multiparametric flow cytometry-chimerism-based approaches are under investigation. This Policy Review highlights the importance of MRD monitoring to enable timely, risk-adapted interventions that encompass both pre-transplantation and post-transplantation periods and can include tailoring conditioning intensity, donor selection, immunosuppression management, donor lymphocyte infusions, and pharmacological therapies such as FLT3 or IDH inhibitors, hypomethylating agents, venetoclax, or menin inhibitors. These recommendations aim to harmonise MRD-driven clinical practice and improve patient outcomes, while identifying key areas for future research.
000305584 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000305584 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305584 650_2 $$2MeSH$$aHumans
000305584 650_2 $$2MeSH$$aNeoplasm, Residual
000305584 650_2 $$2MeSH$$aHematopoietic Stem Cell Transplantation: standards
000305584 650_2 $$2MeSH$$aHematopoietic Stem Cell Transplantation: adverse effects
000305584 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: therapy
000305584 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: pathology
000305584 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: genetics
000305584 650_2 $$2MeSH$$aTransplantation, Homologous
000305584 650_2 $$2MeSH$$aEurope
000305584 650_2 $$2MeSH$$aTransplantation Conditioning
000305584 650_2 $$2MeSH$$aClinical Decision-Making
000305584 7001_ $$0P:(DE-HGF)0$$aBug, Gesine$$b1
000305584 7001_ $$aCiceri, Fabio$$b2
000305584 7001_ $$aCraddock, Charles$$b3
000305584 7001_ $$aDillon, Richard$$b4
000305584 7001_ $$aEsteve, Jordi$$b5
000305584 7001_ $$aPorta, Matteo Giovanni Della$$b6
000305584 7001_ $$aHeuser, Michael$$b7
000305584 7001_ $$ade Leeuw, David C$$b8
000305584 7001_ $$aNagler, Arnon$$b9
000305584 7001_ $$aOnida, Francesco$$b10
000305584 7001_ $$aRoboz, Gail J$$b11
000305584 7001_ $$aRuggeri, Annalisa$$b12
000305584 7001_ $$aSánchez-Ortega, Isabel$$b13
000305584 7001_ $$aSrour, Micha$$b14
000305584 7001_ $$aYakoub-Agha, Ibrahim$$b15
000305584 7001_ $$aBuccisano, Francesco$$b16
000305584 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(25)00426-7$$gVol. 26, no. 11, p. e586 - e596$$n11$$pe586 - e596$$tThe lancet / Oncology$$v26$$x1470-2045$$y2025
000305584 909CO $$ooai:inrepo02.dkfz.de:305584$$pVDB
000305584 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000305584 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000305584 9141_ $$y2025
000305584 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2022$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-17
000305584 915__ $$0StatID:(DE-HGF)9950$$2StatID$$aIF >= 50$$bLANCET ONCOL : 2022$$d2024-12-17
000305584 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK Koordinierungsstelle Frankfurt$$x0
000305584 980__ $$ajournal
000305584 980__ $$aVDB
000305584 980__ $$aI:(DE-He78)FM01-20160331
000305584 980__ $$aUNRESTRICTED